FDA Will Present Brilinta Panel With Alternative Explanation For Negative U.S. Data
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA reviewers discredit AstraZeneca's suggestion that higher doses of aspirin explain ticagrelor's discordant results for U.S. versus overall trial participants - but also offer an alternative reason for the findings.
You may also be interested in...
AstraZeneca's Brilinta Approved With Aspirin Warning
Anti-platelet ticagrelor carries a boxed warning that concomitant aspirin dose must be limited to 100 mg/day, a departure for U.S. prescribers accustomed to high-dose aspirin therapy.
AstraZeneca's Brilinta Approved With Aspirin Warning
Anti-platelet ticagrelor carries a boxed warning that concomitant aspirin dose must be limited to 100 mg/day, a departure for U.S. prescribers accustomed to high-dose aspirin therapy.
Brilinta "Complete Response" Letter Suggests FDA Unswayed On U.S. Efficacy
Agency asks AstraZeneca for additional analyses of data from the 18,000-patient PLATO study, in which no benefit of ticagrelor over clopidogrel was seen in U.S. acute coronary syndrome patients.